参一胶囊联合贝伐单抗治疗晚期卵巢癌提高患者免疫功能的临床观察  

Clinical Observation of Shenyi Capsule Combined with Bevacizumab in the Treatment of Advanced Ovarian Cancer to Improve the Immune Function of Patients

作　　者：陆瑞 周雷[1] 吴志兵[1] 李文清 周瑞[1] 孙璐[1] LU Rui;ZHOU Lei;WU Zhibing;LI Wenqing;ZHOU Rui;SUN Lu(Shuyang County Hospital of Traditional Chinese Medicine,Suqian 223600,China)

机构地区：[1]南京中医药大学沭阳附属医院

出　　处：《中国细胞生物学学报》2019年第9期1787-1792,共6页Chinese Journal of Cell Biology

摘　　要：该文旨在探讨参一胶囊联合贝伐单抗治疗晚期卵巢癌的短期疗效及对外周血Th1/Th2类细胞因子的影响。采用随机数表法,把在该院治疗的88例晚期卵巢癌患者分为治疗组和对照组,每组44例。两组采取紫杉醇联合顺铂化疗。对照组于化疗结束后1 h予贝伐单抗。治疗组在对照组基础上加用参一胶囊。9周后,比较两组短期疗效、不良反应、外周血Th1和Th2细胞水平以及血清干扰素-γ(IFN-γ)、白细胞介素-2(IL-2)、IL-4、IL-10水平。通过比较发现,治疗组短期总有效率显著高于对照组而白细胞减少、血小板减少发生率明显少于对照组(P<0.05);治疗后,治疗组Th1、Th1/Th2及血清IFN-γ、IL-2水平显著高于对照组,Th2及IL-4、IL-10水平显著少于对照组(P<0.01)。该研究证实,参一胶囊联合贝伐单抗治疗晚期卵巢癌可提高短期疗效并能降低化疗带来的部分不良反应,其疗效可能与调节患者体内Th1/Th2类细胞因子有关。This study was to investigate the short-term effect of Shenyi capsule combined with Bevacizumab in treating advanced ovarian cancer and the effect of peripheral blood Th1/Th2 cytokines.Eighty-eight advanced ovarian cancer cases from our hospital were randomly divided into treatment group and control group with 44 in each group referring to number table method.Both groups were given with chemotherapy of Paclitaxel combined with cisplatin.Control group was treated with Bevacizumab 1 h after chemotherapy.On basis of control group,treatment group was treated with Shenyi capsule.After 9 weeks,the short-term effect,adverse drug reaction,peripheral blood level of Th1/Th2,and serum levles of interferon-γ(IFN-γ),interleukin-2(IL-2),IL-4,and IL-10 were compared for both groups.The results showed that the short-term effect of treatment group was obviously higher than control group,and the incidence of leukopenia and thrombocytopenia in the treatment group was significantly lower than that in the control group(P<0.05).Peripheral blood level of Th1 and Th1/Th2 and serum levels of IFN-γand IL-2 of treatment group were obviously higher,while Th2 and IL-4 and IL-10 were less,than those of the control group after treatment(P<0.01).This study confirmed that Shenyi capsule combined with Bevacizumab in treating advanced ovarian cancer can increase the short-term effect,decrease the adverse drug reaction and the regulation of Thl/Th2 cytokines may be related with the efficacy.

关 键 词：参一胶囊 贝伐单抗 卵巢癌 Thl/Th2类细胞因子 

分 类 号：R73[医药卫生—肿瘤]